Fig. 1
From: Oral splicing modulator branaplam in Huntington’s disease: a phase 2 randomized controlled trial
HTT gene transcription and branaplam mode of action. Branaplam modifies the splicing of HTT mRNA, resulting in the inclusion of a pseudoexon which introduces premature stop codons and leads to HTT mRNA decay.
